<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53519">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01724931</url>
  </required_header>
  <id_info>
    <org_study_id>Syntrix-AMT-RA-202</org_study_id>
    <nct_id>NCT01724931</nct_id>
  </id_info>
  <brief_title>Aminopterin Dose Finding Treatment for Methotrexate-Naïve Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 2 Double-Blind, Placebo-Controlled, Randomized Dose Finding Study For The Efficacy And Safety Of Aminopterin In Methotrexate-Naive Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syntrix Biosystems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syntrix Biosystems, Inc.</source>
  <oversight_info>
    <authority>Ukraine: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether aminopterin is effective in the treatment
      of rheumatoid arthritis (RA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, dose ranging study that will
      evaluate the safety, efficacy, and pharmacokinetic properties (the absorption, distribution
      and excretion) of aminopterin following oral administration by subjects with active
      rheumatoid arthritis (≥ 6 tender and ≥ 6 swollen joints) who have not been treated with
      methotrexate (MTX).  Subjects are randomized to one of three treatments: placebo, 1 mg of
      LD-aminopterin, or 3 mg of LD-aminopterin in a 1:1:1 ratio.  The study hypothesis is that
      the 3 mg LD-aminopterin per week is effective at treating rheumatoid arthritis compared to
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>ACR20</measure>
    <time_frame>Study Day 84</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy endpoint, determined at study day 84 or last observation carried forward (LOCF), is the percent of subjects who obtain ACR20 in the 3 mg/week LD-AMT dose compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR20</measure>
    <time_frame>Study Day 84</time_frame>
    <safety_issue>No</safety_issue>
    <description>A secondary efficacy endpoint, determined at study day 84 or LOCF, is the percent of subjects who obtain ACR20 in the 1 mg LD-AMT/week dose.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Event</measure>
    <time_frame>Study Day 126</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, including laboratory measurements of serum chemistry and hematology, and the occurrence of dose-limiting toxicity.  Safety endpoints will be evaluated throughout the study and for an additional 42 days after a subject goes off study.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg LD-Aminopterin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg LD-aminopterin once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg LD-aminopterin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg LD-aminopterin once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LD-aminopterin</intervention_name>
    <arm_group_label>3 mg LD-Aminopterin</arm_group_label>
    <arm_group_label>1 mg LD-aminopterin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt; 18 years of age.

          2. A diagnosis of RA established by the ACR/EULAR 2010 criteria applied to patients who:
             1) have &gt;1 joint with definite clinical synovitis (swelling); 2) with the synovitis
             not better explained by another disease.

        Add scores of categories A-D; a score &gt;6/10 is required for study entry.

        A. Joint involvement:

        1 large joint=0; 2-10 large joints=1; 1-3 small joints (with or without involvement of
        large joints=2; 4-10 small joints (with or without involvement of large joints)=3; &gt;10
        joints (at least 1 small joint)=5.

        B. Serology (at least 1 test result is needed for classification):

        Negative RF and negative ACPA=0; Low-positive RF or low-positive ACPA=2; High-positive RF
        or high-positive ACPA=3.

        C. Acute-phase reactants (at least 1 test result is needed for classification):

        Normal CRP and normal ESR=0; Abnormal CRP or abnormal ESR=1.

        D. Duration of symptoms:

        less than 6 weeks=0; 6 weeks or greater=1.

        3. Class I, II or III functional according to the ACR 1992 revised criteria for the
        classification of global functional status in RA.

        4. RA is active, defined as ≥ 6 swollen joints and ≥ 6 tender joints.

        5. Ability to understand and sign written informed consent.

        6. For sexually active men and for women of childbearing potential, an adequate form of
        contraception.

        7. For pre-menopausal women, a negative pregnancy test, obtained within 1 week prior to
        first study drug dose.

        8. Negative serology for hepatitis B and hepatitis C.

        9. The following screening laboratory blood tests must have the following values, or not
        clinically significant as determined by the PI and Medical Monitor: WBC WNL; absolute
        neutrophil count &gt; lower limit of normal; platelet count WNL; hemoglobin &gt;10.0 g/dL; AST
        WNL.

        10. Adequate renal function: GFR estimated by Cockcroft-Gault formula &gt;60 ml/min

        Exclusion Criteria:

          1. Known history of hepatitis, HIV infection, interstitial lung disease.

          2. Alcohol consumption on a regular basis and unwilling, or unable, to discontinue this
             consumption during the study period.

          3. Prior methotrexate or aminopterin therapy.

          4. Prior biologic drug therapy (e.g., etanercept, adalimumab, infliximab).

          5. Within 2 weeks prior to Study Day 0,  or on Study Day 0, or at any time during the
             study, use of any of the following medications that may result in drug/drug
             interactions with AMT: trimethoprim with or without sulfamethoxazole; sulfonamides;
             sulfonylureas; pyrimethamine; triamethamine; dipyridamole; colchicine; probenecid;
             aminoglycosides; theophylline; phenytoin; and folinic acid (i.e., leucovorin).

          6. At Study Day 0 use of DMARDs and biologics (except antimalarials) including oral or
             injectable gold, azathioprine, penicillamine, sulfasalazine or cyclosporine.
             Subjects previously treated with any of these medications are eligible provided a 28
             day wash-out is completed prior to Study Day 0.  Antimalarial can be continued at the
             same dose if they have been administered at the same dose for 8 weeks before Study
             Day 0, and they will be administered at the same dose throughout the study.  NSAIDs
             or corticosteroid (≤ 10 mg prednisone or equivalent/day) may be continued at the same
             dose if they have been used at a stable dose for two weeks prior to Study Day 0, and
             will be continued at the same doses throughout the study.

          7. Use of corticosteroids in excess of 10 mg prednisone or equivalent/day.

          8. Known concurrent malignancy except basal or squamous cell skin carcinoma, or cervical
             carcinoma in situ.

          9. Concurrent participation in another clinical trial involving experimental treatment
             within 30 days of Study Day 0.

         10. Current and uncontrolled infection, cardiovascular, renal, pulmonary, hepatic or GI
             conditions that will interfere with the conduct of the trial or pose a morbid risk.

         11. Investigator's opinion that a concurrent disease or condition impairs the subject's
             ability to complete the trial: includes psychological, familial, sociological,
             geographical or medical conditions.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Kahn, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Syntrix Biosystems, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tetyana Byelyayeva, M.D., Ph.D.</last_name>
    <phone>(+380 44) 499 56 00</phone>
    <email>Tetyana.Byelyayeva@kcrcro.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Viktor Dzyuba</last_name>
    <phone>(+380 44) 499 56 00</phone>
    <email>Viktor.Dzyuba@kcrcro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre of Immunobiologic Therapy, State Institution &quot;Institute of Emergency and Reconstructive Surgery</name>
      <address>
        <city>Donets'k</city>
        <zip>83045</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andriy Gnylorybov, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Viktoria Ridzhok, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuliia Hushchyna, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hospital Therapy #1, Regional Clinical Hospital for occupational diseases 104</name>
      <address>
        <city>Donetsk</city>
        <zip>83059</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vadym Berenfus, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristina Tyumyenyeva, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vitaliy Tolstoy, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Viktoriia Balatsko, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal Establishment of Health Protection, Regional Hospital of Veterans of War, Rheumatology Department</name>
      <address>
        <city>Kharkiv</city>
        <zip>61137</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anatolii Oparin, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oleksii Oparin, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalia Lavrova, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Communal Establishment of Health Protection &quot;Kharkiv City Clinical Hospital #8&quot;</name>
      <address>
        <city>Kharkiv</city>
        <zip>61178</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vira Tseluyko, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olha Radchenko, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Scientific Center &quot;M.D. STRAZHESKO INSTITUTE OF CARDIOLOGY, MAS OF UKRAINE&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>03151</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Volodymyr Kovalenko, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Galyna Protsenko, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology and Allergology, Kyiv Regional Clinical Hospital №1</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Grygorii Lysenko, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ludmila Khimion, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Svetlana Danyliuk, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Clinical Hospital, Department of Rheumatology</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Orest Abrahamovych, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulyana Abrahamovych, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iaryna Liaschuk, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omelian Synenkii, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardio-Rheumatology, Communal Institution &quot;Odesa Regional Clinical Hospital&quot;</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olena Levchenko, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andriy Yurkiv, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maryna Kuznetsova, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bogdana Scherbakova, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Crimean State Medical University n.a. S.I. Georgievsky based on Rheumatology Department of Crimean Republic Institution &quot;Clinical Territorial Medical Association &quot;University Clinic&quot;</name>
      <address>
        <city>Simferopol</city>
        <zip>95017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Galyna Koshukova, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andriy Petrov, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Railway Clinical Hospital of Uzhorod Station of Lviv Railroad Administration, Therapeutic Department</name>
      <address>
        <city>Uzhorod</city>
        <zip>88009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ivan Chopey, MD, PhD, Dr Sc D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yaroslav Mykhalko, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samvel Turianytsia, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Vinnytsya Regional Clinical Hospital n.a. M.I</name>
      <address>
        <city>Vinnytsa</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mykola Stanislavchuk, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Galyna Movchan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zaporizhzhya City Multiple Discipline Clinical Hospital #9, Department of Therapy</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69065</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Volodymyr Koshlia, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivan Isaichykov, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Therapy, City Clinical Hospital № 6</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oleg Kraydashenko, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Halyna Svetlytska, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Buidenko, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Zaporizhzhia Regional Clinical Hospital</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dmyto Rekalov, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ganna Prytkova, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Viktoria Krupko, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Therapy, City Hospital № 7</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vadym Vizir, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oleksandr Goncharov, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anton Sadomov, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <results_reference>
    <citation>Menter A, Thrash B, Cherian C, Matherly LH, Wang L, Gangjee A, Morgan JR, Maeda DY, Schuler AD, Kahn SJ, Zebala JA. Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter. J Pharmacol Exp Ther. 2012 Sep;342(3):696-708. doi: 10.1124/jpet.112.195479. Epub 2012 May 31.</citation>
    <PMID>22653877</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 17, 2014</lastchanged_date>
  <firstreceived_date>November 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antifolate</keyword>
  <keyword>antiinflammatory</keyword>
  <keyword>autoimmune disease</keyword>
  <keyword>hematological treatment</keyword>
  <keyword>rheumatic disease</keyword>
  <keyword>folic acid antagonist</keyword>
  <keyword>enzyme inhibitor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aminopterin</mesh_term>
    <mesh_term>Folic Acid Antagonists</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
